Abstract
Introduction: The treatment of leishmaniasis in humans faces challenges such as drug resistance and treatment abandonment. In this context, the search for an effective vaccine is crucial as a prophylactic measure. This study compares drug treatment and vaccination.
Methodology: An integrative review was carried out with the descriptors "leishmaniasis", "treatment", "vaccine" and "prevention" in databases such as PUBMED, Scielo, Medscape and DATASUS Tabnet.Results: Drug treatment includes three lines of medications, each with distinct challenges. On the other hand, vaccination is seen as a primary measure of immunoprophylaxis, with different generations of vaccines, including those based on the parasite's DNA. Discussion: In developing countries, such as Brazil, the need for effective and accessible treatment is pressing. Vaccination has advantages in cost and effectiveness, but more studies are needed to consolidate this form of prevention. Final Considerations: Investing in vaccines against leishmaniasis offers advantages in cost and effectiveness compared to drug treatment. Given the failures of conventional treatment, vaccination emerges as a promising prevention strategy.
DOI:https://doi.org/10.56238/sevened2024.018-043